Drug Development Global Program

DRG_homepage-img-18120_Jun2016

PATH’s Drug Development program is committed to ensuring that safe and effective medicines are available and accessible to all those who need them.

Guided by a passion for health equity, we work with public- and private-sector stakeholders to develop and advance medicines that prevent and treat diseases disproportionately affecting women and children in low-resource settings. Our areas of focus include enteric and diarrheal diseases, neglected tropical diseases, HIV/AIDS, and malaria.

Like all of PATH’s work, our efforts are rooted in a deep commitment to health equity and our bold belief in the power of innovation to save lives. Find out more »


The cast behind a life-changing drug

How a consortium of global experts, partners, and funders is working to get an underutilized drug into the hands of communities affected by debilitating parasitic worms. Learn more »

Highlights

in the news: Expanding access to medicines and technologies by expanding the dialogue »

press release: PATH, Clarus, and the Global Health Investment Fund announce an innovative $25 Million financing arrangement to improve treatment of intestinal worms »

on our blog: Oxygen for the most vulnerable: WFSA supports advocacy initiative »


Our work

Stopping diarrhea deaths

Confronting neglected tropical diseases

Addressing HIV/AIDS

drg-area-button-malaria


Sign up for our e-newsletter

DD-home-enewsSubscribe to our e-newsletter, A Healthy Dose, for a quarterly update on our work. Each issue features reports from the field, news on the latest clinical trial milestones, and resources in nonprofit drug development. Subscribe now »



Photos from top (clockwise from left): PATH/Rocky Prajapati, PATH/Georgina Goodwin, PATH/Matthew Dakin, and PATH/Gabe Bienczycki.